Alzamend Neuro (ALZN) Competitors $2.91 +0.01 (+0.34%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALZN vs. LSB, TRAW, TSBX, JBIO, GTBP, NLSP, AEON, ORGS, OBSV, and BMRAShould you be buying Alzamend Neuro stock or one of its competitors? The main competitors of Alzamend Neuro include LakeShore Biopharma (LSB), Traws Pharma (TRAW), Turnstone Biologics (TSBX), Jade Biosciences (JBIO), GT Biopharma (GTBP), NLS Pharmaceutics (NLSP), AEON Biopharma (AEON), Orgenesis (ORGS), ObsEva (OBSV), and Biomerica (BMRA). These companies are all part of the "pharmaceutical products" industry. Alzamend Neuro vs. Its Competitors LakeShore Biopharma Traws Pharma Turnstone Biologics Jade Biosciences GT Biopharma NLS Pharmaceutics AEON Biopharma Orgenesis ObsEva Biomerica Alzamend Neuro (NASDAQ:ALZN) and LakeShore Biopharma (NASDAQ:LSB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk. Which has stronger earnings & valuation, ALZN or LSB? Alzamend Neuro has higher earnings, but lower revenue than LakeShore Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlzamend NeuroN/AN/A-$9.95MN/AN/ALakeShore Biopharma$80.82M0.12-$61.09MN/AN/A Is ALZN or LSB more profitable? LakeShore Biopharma's return on equity of 0.00% beat Alzamend Neuro's return on equity.Company Net Margins Return on Equity Return on Assets Alzamend NeuroN/A -497.73% -147.21% LakeShore Biopharma N/A N/A N/A Do insiders & institutionals believe in ALZN or LSB? 49.6% of Alzamend Neuro shares are owned by institutional investors. Comparatively, 52.6% of LakeShore Biopharma shares are owned by institutional investors. 30.2% of Alzamend Neuro shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media favor ALZN or LSB? In the previous week, Alzamend Neuro and Alzamend Neuro both had 1 articles in the media. Alzamend Neuro's average media sentiment score of 1.89 equaled LakeShore Biopharma'saverage media sentiment score. Company Overall Sentiment Alzamend Neuro Very Positive LakeShore Biopharma Very Positive Do analysts prefer ALZN or LSB? Alzamend Neuro presently has a consensus price target of $180.00, indicating a potential upside of 6,085.57%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, equities research analysts clearly believe Alzamend Neuro is more favorable than LakeShore Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alzamend Neuro 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00LakeShore Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, ALZN or LSB? Alzamend Neuro has a beta of -0.27, suggesting that its share price is 127% less volatile than the S&P 500. Comparatively, LakeShore Biopharma has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. SummaryAlzamend Neuro and LakeShore Biopharma tied by winning 5 of the 10 factors compared between the two stocks. Get Alzamend Neuro News Delivered to You Automatically Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALZN vs. The Competition Export to ExcelMetricAlzamend NeuroMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.33M$2.82B$5.46B$8.91BDividend YieldN/A2.71%5.36%4.15%P/E RatioN/A21.2926.4619.70Price / SalesN/A251.58404.54108.31Price / CashN/A41.2925.8827.49Price / Book-0.097.247.925.42Net Income-$9.95M-$55.05M$3.15B$248.34M7 Day Performance-1.36%1.83%2.20%2.41%1 Month Performance-27.79%6.06%4.39%4.80%1 Year Performance-91.80%0.66%32.26%17.50% Alzamend Neuro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALZNAlzamend Neuro3.4177 of 5 stars$2.91+0.3%$180.00+6,085.6%-91.8%$2.33MN/A0.004LSBLakeShore Biopharma1.0804 of 5 stars$0.97flatN/AN/A$9.03M$80.82M0.00773Gap DownTRAWTraws Pharma0.327 of 5 stars$1.59+2.3%N/AN/A$8.81M$230K-0.0517News CoverageNegative NewsAnalyst UpgradeTSBXTurnstone Biologics1.6714 of 5 stars$0.38+2.4%$0.45+19.4%-86.5%$8.72M$19.31M-0.1482JBIOJade Biosciences2.6525 of 5 stars$10.10+2.3%$14.00+38.6%N/A$8.48MN/A-0.1720Positive NewsGTBPGT Biopharma1.9639 of 5 stars$3.25+1.2%$11.00+238.5%+25.1%$8.42MN/A-0.578News CoverageNLSPNLS PharmaceuticsN/A$2.28-2.1%N/A+1,186.3%$8.20MN/A0.006News CoverageAEONAEON Biopharma3.4428 of 5 stars$0.72+1.6%$360.00+49,969.5%-99.0%$8.13MN/A3.995Positive NewsORGSOrgenesis1.7985 of 5 stars$1.69-3.1%N/AN/A$8.11M$662K0.00150OBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150BMRABiomerica0.4396 of 5 stars$3.10+2.3%N/A-10.5%$7.91M$5.41M-1.3460Negative News Related Companies and Tools Related Companies LakeShore Biopharma Competitors Traws Pharma Competitors Turnstone Biologics Competitors Jade Biosciences Competitors GT Biopharma Competitors NLS Pharmaceutics Competitors AEON Biopharma Competitors Orgenesis Competitors ObsEva Competitors Biomerica Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALZN) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Shock (insane new prediction)World Gold Council reports: "No sign" of this catalyst slowing A whopping 73% of Americans report they're "...Stansberry Research | SponsoredWhy Is President Trump Fast-Tracking These Companies?Forget about AI… There's a hot new trend on Wall Street… And it's all thanks to President Trump. His ...InvestorPlace | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alzamend Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alzamend Neuro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALZN Stock Alerts